CN105535826A - Pharmaceutical composition for treating cat fatty liver and preparation method thereof - Google Patents

Pharmaceutical composition for treating cat fatty liver and preparation method thereof Download PDF

Info

Publication number
CN105535826A
CN105535826A CN201511017275.7A CN201511017275A CN105535826A CN 105535826 A CN105535826 A CN 105535826A CN 201511017275 A CN201511017275 A CN 201511017275A CN 105535826 A CN105535826 A CN 105535826A
Authority
CN
China
Prior art keywords
parts
radix
pharmaceutical composition
rhizoma
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201511017275.7A
Other languages
Chinese (zh)
Inventor
王开
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI TRUELAND INFORMATION TECHNOLOGY Co Ltd
Original Assignee
SHANGHAI TRUELAND INFORMATION TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI TRUELAND INFORMATION TECHNOLOGY Co Ltd filed Critical SHANGHAI TRUELAND INFORMATION TECHNOLOGY Co Ltd
Priority to CN201511017275.7A priority Critical patent/CN105535826A/en
Publication of CN105535826A publication Critical patent/CN105535826A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of veterinary drugs, and discloses a pharmaceutical composition for treating cat fatty liver as well as a preparation method and application thereof. The pharmaceutical composition is prepared from the raw materials of herba phyllanthi urinariae, clethra loosestrife herb, muskmelon base, glossy privet fruit, eucommia bark, Sinkiang arnebia root, white puncturevine caltrop fruit, common cephalanoplos herb, flower of lobed kudzuvine, giant knotweed rhizome, capillary wormwood herb, tiflawn, turmeric root-tuber, raw rhubarb, Chinese thorowax root, oriental waterplantain rhizome, pinellia tuber, cassia seed, tangerine peel, peach seed, choline chloride, and ursodesoxycholic acid according to certain weight parts. The pharmaceutical composition is simple in formula, has significant effects of clearing heat, removing fat, protecting the liver, dissipating blood stasis, excreting dampness, invigorating the spleen, promoting the circulation of qi, reducing phlegm, arresting bleeding, and soothing the liver to remove fat by virtue of organic combination, dialectic compatibility and mutual assistance, and can be used for effectively treating cat fatty liver syndromes. Clinical treatment statistics prove that the cure rate can reach 88.89%, and the effective rate is 100%. The preparation method of the pharmaceutical composition disclosed by the invention keeps active ingredients of each raw material to the maximum extent and is simple to operate, and the pharmaceutical composition does not have toxic or side effects, is easy to absorb by a diseased cat, and is suitable for industrial production.

Description

A kind ofly treat pharmaceutical composition of cat fatty liver and preparation method thereof
Technical field
The present invention relates to veterinary drug technical field, be specifically related to a kind ofly treat pharmaceutical composition of cat fatty liver and its preparation method and application.
Background technology
Cat fatty liver syndrome is the disease of the liver enlargement caused in liver cell due to lipid storage.Liver due to cat has special lipopexia ability, therefore this disease has specificity to cat, easily causes hepatocyte injury.Clinical data proves, cat fatty liver syndrome is the modal hepatic disease of cat.Most of fatty liver suffers from cat can there is hepatic disease, and this disease is modal disease in cat hepatic disease.The Fatty Liver Disease of cat is relative to the fatty liver of dog, more serious than dog, as treatment usually can cause death not in time.Cat fatty liver syndrome is regardless of kind, and the sickness rate of female cat, higher than tom, is not eaten food with premorbid a period of time, and during this period of time before fatter geriatric cat common.
The syndromic cause of disease of Primary Fatty Liver is very clear and definite, from clinical data statistics, first with stress be relevant, as got a fright, flip-flop environment, change cat grain, owner stays out, family has new house pet etc., is all inducement.Next is trophic factor, as overnutrition, and the food of the higher fatty acid and Hi CHO of Long-term Feeding; Or nutrition is inadequate, in long-term hungry or feedstuff, lack protein, vitamin, methionine, arginine etc., hypomotility in addition, or liver is subject to toxin damage etc. for a long time and all can causes.In addition, in hypomotility, anoxia and body, the material deficiency etc. of anti-fatty acid, also can cause morbidity.
The pathogeny of cat fatty liver syndrome is understood fully not yet completely, it is generally acknowledged, cat is subject to the stressors such as change, daily ration replacing, scaring of environment, or after disease causes anorexia to continue many days, just having a large amount of peripheries steatolysis is that fatty acid enters liver, because cat is different from other animals, itself relatively lacks sufficient efficient protein matter deposit, once can not obtain from food source, just energy supply can only be carried out by the fat consuming self.These fatty acids enter liver cell mitochondria and carry out the participation that beta-oxidation needs L-BETAIN, and very low density lipoprotein (VLDL) also can be become to transport from liver transfer with protein bound.In pathological conditions, suffer from cat due to anorexia, make proper interior L-BETAIN and protein, especially methionine is relative with arginine or definitely lack, affect the acyl coA that extramitochondrial free fatty acid or activation produce and enter mitochondrial internal, cause fatty acid in liver can not metabolism normally and transhipment, and accumulate at liver with the form of triglyceride,, there is metabolism disorder in the physiological function that liver can not be brought into normal play.There are statistics, when the lipid material content of liver exceedes 5% of liver gross weight, just can cause fatty liver.
The trouble cat age of fatty liver is generally bigger than normal, and the bodily form is fat, is more common in female.Early stage visible tired mind, drowsy, general weakness, sleeping how vertical few, be slow in action, loss of appetite and even absolutely useless.Along with the development body weight of the state of an illness declines gradually, dehydration, some trouble cat body temperature raises.Due to urine in have bilirubin to make urine be buff, and bilirubin enter intestinal reduce make feces be white.Time and occur diarrhoea, or diarrhoea and constipation alternately occur.There is vomiting, abdominal distention and sialorrhea in some trouble cats.The morbidity later stage can see place's xanthochromias such as visual mucosa, gums and internal ear, and occur amyotrophy in various degree, abdominal touch can perception liver enlargement.Sick to the later stage have a convulsion, the nervous symptoms such as stupor, finally die of exhaustion.
Lab testing suffers from cat anemia, and total white blood cells increases, and mean corpuscular volume (MCV), mean corpusular hemoglobin increase, and total number of blood platelet reduces, and illustrates that blood clotting ability declines.Serum biochemistry inspection display, suffers from cat alkali phosphatase (SALP), alanine aminotransferase (ALT), aspartate amino transferase (AST) rising.The change of activity of serum enzyme contributes to the pathological state reflecting liver, and this three enzyme raises and shows that the trouble cat bile stasis of blood is stagnant, hepatocyte is impaired, and sick cat suffers from hepatitis; Total protein raises and shows because dehydration causes pachyemia and chronic inflammatory disease; Bilirubin raises and shows that suffering from cat has latent jaundice, has hemolytic disease, hepatic disease; Creatinine rises and shows that detection of glomeruli filtration function is impaired, and kidney sustains damage; T-CHOL and triglyceride excessively raise, and show to suffer from cat obesity, and hyperlipemia, fatty liver etc., easily suffer from cardiovascular disease.Imaging examination, the display of x mating plate is suffered from cat liver morphology and is increased.The visible liver enlargement of B ultrasonic, echo dispersivity strengthens, and in liver, echo intensity successively decreases with the degree of depth, and in liver, blood vessel wall echo is weakened or shows unclear.Urine examination urine is dark yellow, muddiness, glucose feminine gender, protein negative, bilirubin raise, and illustrates and occurs jaundice and hepatocyte injury.According to inquiring, clinical symptoms, blood test, imaging examination and urine examination, cat fatty liver syndrome can be diagnosed as.
The treatment of current cat fatty liver syndrome, mostly is clinically use Western medicine merely, to reduce the dirty middle fat content of Hepar Felis domestica.Although temporarily can delay the state of an illness, cure the symptoms, not the disease, curative effect is also unsatisfactory.And adopt the method treatment cat fatty liver syndrome of Integrated TCM, and there is original advantage, cheap, toxic and side effects is little, source is wide, not only cost-saving, and can symptom management in the short period of time, the death of minimizing cat.Therefore, a kind of Chinese and western medicinal composition for cat fatty liver syndrome is badly in need of, for clinical practice.
Summary of the invention
In view of this, the present invention seeks to the defect for prior art, provide a kind of and treat pharmaceutical composition of cat fatty liver and its preparation method and application.The pharmaceutical composition for the treatment of cat fatty liver of the present invention is combined by Chinese medicine and Western medicine, have overall curative effect high, not easily produce the advantages such as drug resistance, residual low, toxic and side effects is little.Preparation method of the present invention is drawn materials easily, cost is low, simple to operate, be widely used in industrialization produces.
For realizing object of the present invention, the present invention adopts following technical scheme:
A kind of pharmaceutical composition, be made up of the crude drug of following weight portion:
Cacumen Securinegae Suffruticosae 40-60 part, Herba Lysimachiae Clethroids 40-60 part, Pedicellus Melo 40-60 part, Fructus Ligustri Lucidi 30-50 part, Cortex Eucommiae 30-50 part, Radix Arnebiae (Radix Lithospermi) 30-50 part, Flos puerariae lobatae 30-50 part, Rhizoma Polygoni Cuspidati 30-50 part, Fructus Atriplicis Sibiricae 20-40 part, Herba Cirsii 20-40 part, Herba Artemisiae Scopariae 20-40 part, paradise grass 20-40 part, Radix Curcumae 20-40 part, Radix Et Rhizoma Rhei 20-40 part, Radix Bupleuri 20-40 part, Rhizoma Alismatis 15-35 part, Rhizoma Pinelliae 15-35 part, Semen Cassiae 15-35 part, Pericarpium Citri Reticulatae 15-35 part, Semen Persicae 10-30 part, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
In some embodiments, described in pharmaceutical composition of the present invention, raw material medicines in portions by weight number is: Cacumen Securinegae Suffruticosae 60 parts, Herba Lysimachiae Clethroids 60 parts, Pedicellus Melo 60 parts, Fructus Ligustri Lucidi 50 parts, the Cortex Eucommiae 50 parts, Radix Arnebiae (Radix Lithospermi) 50 parts, Flos puerariae lobatae 50 parts, Rhizoma Polygoni Cuspidati 50 parts, Fructus Atriplicis Sibiricae 40 parts, Herba Cirsii 40 parts, Herba Artemisiae Scopariae 40 parts, paradise grass 40 parts, Radix Curcumae 40 parts, Radix Et Rhizoma Rhei 40 parts, Radix Bupleuri 40 parts, Rhizoma Alismatis 35 parts, the Rhizoma Pinelliae 35 parts, Semen Cassiae 35 parts, Pericarpium Citri Reticulatae 35 parts, 30 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
In some embodiments, described in pharmaceutical composition of the present invention, raw material medicines in portions by weight number is: Cacumen Securinegae Suffruticosae 40 parts, Herba Lysimachiae Clethroids 40 parts, Pedicellus Melo 40 parts, Fructus Ligustri Lucidi 30 parts, the Cortex Eucommiae 30 parts, Radix Arnebiae (Radix Lithospermi) 30 parts, Flos puerariae lobatae 30 parts, Rhizoma Polygoni Cuspidati 30 parts, Fructus Atriplicis Sibiricae 20 parts, Herba Cirsii 20 parts, Herba Artemisiae Scopariae 20 parts, paradise grass 20 parts, Radix Curcumae 20 parts, Radix Et Rhizoma Rhei 20 parts, Radix Bupleuri 20 parts, Rhizoma Alismatis 15 parts, the Rhizoma Pinelliae 15 parts, Semen Cassiae 15 parts, Pericarpium Citri Reticulatae 15 parts, 10 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
In some embodiments, described in pharmaceutical composition of the present invention, raw material medicines in portions by weight number is: Cacumen Securinegae Suffruticosae 50 parts, Herba Lysimachiae Clethroids 50 parts, Pedicellus Melo 50 parts, Fructus Ligustri Lucidi 40 parts, the Cortex Eucommiae 40 parts, Radix Arnebiae (Radix Lithospermi) 40 parts, Flos puerariae lobatae 40 parts, Rhizoma Polygoni Cuspidati 40 parts, Fructus Atriplicis Sibiricae 30 parts, Herba Cirsii 30 parts, Herba Artemisiae Scopariae 30 parts, paradise grass 30 parts, Radix Curcumae 30 parts, Radix Et Rhizoma Rhei 30 parts, Radix Bupleuri 30 parts, Rhizoma Alismatis 25 parts, the Rhizoma Pinelliae 25 parts, Semen Cassiae 25 parts, Pericarpium Citri Reticulatae 25 parts, 20 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
Present invention also offers the preparation method of described pharmaceutical composition, comprising:
Step 1: take Herba Lysimachiae Clethroids, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Rhizoma Polygoni Cuspidati, paradise grass, Radix Et Rhizoma Rhei, Semen Cassiae pulverizing by proportioning raw materials, reflux, extract, after ethanol merceration, collecting by filtration filtrate;
Step 2: take Cacumen Securinegae Suffruticosae, Pedicellus Melo, Fructus Ligustri Lucidi, Herba Cirsii, Flos puerariae lobatae, Herba Artemisiae Scopariae, Radix Curcumae, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Semen Persicae pulverizing by proportioning raw materials, collect filtrate after water extraction;
Step 3: step gained filtrate and step 2 gained filtrate are merged, adds choline chloride powder and Ursodeoxycholic Acid Tablets by proportioning.
In some embodiments, in the preparation method of pharmaceutical composition of the present invention, ethanol merceration described in step 1 is the medical material that 90% ethanol submergence is pulverized, dipping 1d.
In some embodiments, in the preparation method of pharmaceutical composition of the present invention, reflux, extract, described in step 1 is reflux, extract, 1-3 time, each 30min-60min.
In some embodiments, in the preparation method of pharmaceutical composition of the present invention, water extraction described in step 2 is taken as and adds 8 times of water gagings, and 65 DEG C are extracted 1-3 time, each 3-6h.
In some embodiments, containing crude drug 1.28g/mL-1.42g/mL in pharmaceutical composition described in the preparation method of pharmaceutical composition of the present invention.
Present invention also offers pharmaceutical composition prepared by described preparation method.
Present invention also offers the application of described pharmaceutical composition in the medicine of preparation treatment cat fatty liver.
Present invention also offers a kind of pharmaceutical preparation, by effective dose pharmaceutical composition of the present invention and adjuvant can be accepted form.
Pharmaceutical composition of the present invention selects Cacumen Securinegae Suffruticosae, Herba Lysimachiae Clethroids, Pedicellus Melo, Fructus Ligustri Lucidi, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Herba Cirsii, Flos puerariae lobatae, Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, paradise grass, Radix Curcumae, Radix Et Rhizoma Rhei, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Semen Cassiae, Pericarpium Citri Reticulatae, Semen Persicae and choline chloride, ursodesoxycholic acid to make by certain part by weight, formula is simple, organic assembling, dialectical compatibility and mutually assisting a ruler in governing a country, have that significant heat clearing away dispels that fat protects the liver, dissipating blood stasis eliminating dampness by diuresis spleen invigorating, promoting the circulation of QI and reducing phlegm hemostasia effect, soothing the liver fat of dispelling, can effectively treat cat fatty liver syndrome.Through clinical treatment statistical confirmation, cure rate can reach 88.89%, effective percentage 100%.Herba Lysimachiae Clethroids, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Rhizoma Polygoni Cuspidati, paradise grass, Radix Et Rhizoma Rhei, Semen Cassiae are pulverized by the preparation method of pharmaceutical composition of the present invention, reflux, extract, after ethanol merceration, collecting by filtration filtrate, Cacumen Securinegae Suffruticosae, Pedicellus Melo, Fructus Ligustri Lucidi, Herba Cirsii, Flos puerariae lobatae, Herba Artemisiae Scopariae, Radix Curcumae, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Semen Persicae are pulverized, after water extraction, collects filtrate, two filtrates merge, add choline chloride powder and Ursodeoxycholic Acid Tablets to obtain, farthest remain the effective ingredient of each raw material, solve Chinese medicine powder crude fiber content high simultaneously, effective ingredient is difficult to the deficiency of stripping, use convenient, absorb rapidly, the medicine composite for curing cat fatty liver syndrome Be very effective prepared, crude drug source is extensive simultaneously, cost is low, simple to operate, have no side effect, not easily produce drug resistance, be easy to suffer from cat absorb, be suitable for suitability for industrialized production, for promoting that the sound development of raising pets industry has very important economy and social meaning.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, be clearly and completely described the technical scheme in the embodiment of the present invention, obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
To achieve these goals, the invention provides following technical scheme:
A kind of pharmaceutical composition, be made up of the crude drug of following weight portion:
Cacumen Securinegae Suffruticosae 40-60 part, Herba Lysimachiae Clethroids 40-60 part, Pedicellus Melo 40-60 part, Fructus Ligustri Lucidi 30-50 part, Cortex Eucommiae 30-50 part, Radix Arnebiae (Radix Lithospermi) 30-50 part, Flos puerariae lobatae 30-50 part, Rhizoma Polygoni Cuspidati 30-50 part, Fructus Atriplicis Sibiricae 20-40 part, Herba Cirsii 20-40 part, Herba Artemisiae Scopariae 20-40 part, paradise grass 20-40 part, Radix Curcumae 20-40 part, Radix Et Rhizoma Rhei 20-40 part, Radix Bupleuri 20-40 part, Rhizoma Alismatis 15-35 part, Rhizoma Pinelliae 15-35 part, Semen Cassiae 15-35 part, Pericarpium Citri Reticulatae 15-35 part, Semen Persicae 10-30 part, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
Tradition veterinary thinks that the relation of liver and spleen is very close, on physiology, and liver controlling conveyance and dispersion, The spleen has the function to transport and transform nutrients; Blood stored in the liver, the spleen governs the blood.Spleen obtains the catharsis of liver, then coordination between ascending and descending, and transportation capabilities are healthy and vigorous.On pathology, liver spleen also influences each other, if the liver failing to maintain the normal flow of QI, can cause " the liver failing to dredge the spleen "; If insufficiency of the spleen mistake fortune, no resource of generating and transforming QI and blood, then liver is without grown.Due to pet cat Long-term Feeding high-energy feed, quantity of motion is not enough in addition, and work and rest is not normal, coup injury taste, causes essence of water and grain not spread to whole body by spleen and to turn to phlegm-damp.Liver has ascension yang-energy all over the body, the effect of harmonizing the functional activities of vital QI.Due to the characteristic that irritability has main liter to send out, therefore its pathogenesis is let out too for common to rise, and shows as the pathological change such as excessive rising of liver-YANG or upward invasion of liver-QI more.Therefore have again saying of " irritability liver YANG often being in excess ".Irritability is had a surplus, liver with for, liver body is got involved, thus on the one hand due to the stagnation of QI blood be obstructed, liver blood secretly consumes and not enough on the one hand.So the formation of cat fatty liver syndrome is because the liver failing to maintain the normal flow of QI, spleen fortune lose strong, the turbid pent-up of retention of damp-heat in the interior, expectorant, stagnation of blood stasis and finally cause damp-phlegm stasis blocking liver venation, micro-for foodstuff essence normally distribution can not be transported to whole body everywhere by body, thus generation fat, liquid phlegm-damp are accumulated among skin, internal organs, cause a series of clinical symptoms and the sign of fatty liver.Therefore for its pathogenesis, treatment protects the liver based on heat clearing away fat of dispelling, hold concurrently with dissipating blood stasis eliminating dampness by diuresis spleen invigorating, promoting the circulation of QI and reducing phlegm hemostasis.Applicant is in conjunction with modern Chinese medicine pharmacy and research practice experience for many years, select Cacumen Securinegae Suffruticosae, Herba Lysimachiae Clethroids, Pedicellus Melo, Fructus Ligustri Lucidi, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Herba Cirsii, Flos puerariae lobatae, Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, paradise grass, Radix Curcumae, Radix Et Rhizoma Rhei, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Semen Cassiae, Pericarpium Citri Reticulatae, Semen Persicae two Ten Herbs material is equipped with choline chloride, Ursodeoxycholic Acid Tablets is raw material, make according to constant weight prescription.
Wherein, Cacumen Securinegae Suffruticosae mildly bitter flavor, sweet, cool in nature, nontoxic, enter liver spleen channel, there is effect of heat clearing away suppressing the hyperactive liver, liver heat removing and eyesight improving, dysentery relieving diuresis.
Herba Lysimachiae Clethroids sweet in the mouth, warm in nature, there is effect of suppressing the hyperactive liver spleen invigorating, heat clearing and blood circulation promoting.
Semen Cassiae sweet in the mouth, hardship, cold nature, returns liver, gallbladder, kidney three warp, has effect of heat clearing away, improving eyesight, intestine moistening.
Cacumen Securinegae Suffruticosae, Herba Lysimachiae Clethroids, Semen Cassiae three medicine share, and have significant heat clearing away suppressing the hyperactive liver, the merit of fat spleen invigorating of dispelling, the monarch drug in common composition pharmaceutical composition.
Rhizoma Polygoni Cuspidati mildly bitter flavor, cold nature, returns liver, gallbladder, lung meridian, and energy dampness removing jaundice eliminating, heat-clearing and toxic substances removing, eliminating stasis to stop pain reduce phlegm, and are used for treating jaundice due to damp-heat, stranguria with turbid discharge, the cards such as lump in the abdomen.
Herba Artemisiae Scopariae bitter in the mouth, cold nature, enters spleen, stomach, liver, gallbladder meridian, and the bitter diarrhea of its property falls, and has effect of eliminating damp-heat, clearind deficient heat, sharp jaundice.
Pedicellus Melo bitter in the mouth, cold in nature, return liver, spleen, stomach warp, there is the effect of fat the liver protecting and ALT lowering of dispelling.
Fructus Atriplicis Sibiricae acrid in the mouth, hardship, slightly warm in nature, enters liver, lung meridian, has effect of dispersing the stagnated live-QI to relieve the stagnation of QI, dispelling pathogenic wind for improving eyesight.
Radix Curcumae acrid in the mouth, hardship, cold in nature, enter liver, the heart, lung meridian, have that removing heat from blood clears away heart-fire, promoting QI circulation for relieving depression, stasis-dispelling and pain-killing, promoting the function of the gallbladder to alleviate jaundice effect.
Radix Bupleuri bitter in the mouth, cold nature, enters liver, gallbladder, pericardium, tri-jiao channel, and antipyretic effect is better, and for treating SHAO YANG disease by mediation warp, property is apt to catharsis, has good dispersing the stagnated live-QI to relieve the stagnation of QI effect, cures mainly depression of liver-QI.
Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, Pedicellus Melo three medicine share, and have significant clearing away heat-damp and promoting diuresis, effect that dissipating blood stasis protects the liver.Fructus Atriplicis Sibiricae, Radix Curcumae, Radix Bupleuri three medicine share, and have effect of significant dispersing the stagnated live-QI to relieve the stagnation of QI, promoting the circulation of QI to relieve pain.Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, Pedicellus Melo, Fructus Atriplicis Sibiricae, Radix Curcumae, the Radix Bupleuri 6 taste medicine ministerial drug jointly in the side of composition.
Fructus Ligustri Lucidi sweet-bitter flavor, cool in nature, return Liver and kidney warp, there is nourishing the liver and kidney, effect that tonifying YIN nourishes blood.
Cortex Eucommiae sweet in the mouth, warm in nature, return liver, kidney channel, there is effect of invigorating the liver and kidney, strong waist knee joint, bone and muscle strengthening.
Flos puerariae lobatae nature and flavor are sweet, cool in nature, enter liver, stomach warp, have effect of heat-clearing and toxic substances removing, liver protecting and kidney invigorating.
Fructus Ligustri Lucidi, the Cortex Eucommiae, Flos puerariae lobatae three medicine are share, and have the effect of good the liver and the kidney tonifying, bone and muscle strengthening improving eyesight.
Radix Arnebiae (Radix Lithospermi) bitter in the mouth, cold in nature, enter percardium, Liver Channel, have effect of removing heat from blood and promoting blood circulation, heat-clearing and toxic substances removing, multiplexly control jaundice due to damp-heat, purpura and various go out blood disorder etc.
Herba Cirsii sweet in the mouth, hardship, cool in nature, GUIXIN, Liver Channel, have effect of cooling blood for hemostasis, removing blood stasis to reduce swelling, for various go out blood disorder.
Semen Persicae sweet in the mouth, hardship, property is put down, and enters liver, lung, large intestine channel, has removing blood stasis, moisturizes effect of laxation.
Radix Et Rhizoma Rhei bitter in the mouth, cold in nature, enter spleen, stomach, large intestine, liver, pericardium channel, there is stasis removing, purging fire and cooling blood, effect of blood circulation promoting and blood stasis dispelling.
Radix Arnebiae (Radix Lithospermi), Herba Cirsii, Semen Persicae, Radix Et Rhizoma Rhei four medicine compatibility, play cooling blood for hemostasis, effect that blood stasis dispelling disappears fat in side.
Paradise grass bitter in the mouth, micro-sweet, cool in nature, returns lung, spleen, kidney channel, has the effect of heat-clearing and toxic substances removing, replenishing QI to invigorate the spleen, preventing phlegm from forming and stopping coughing.
Rhizoma Pinelliae acrid in the mouth, warm in nature, enter spleen, stomach warp, there is the effect of stopping nausea and vomiting by lowering the adverse flow of QI, removing dampness and eliminating phlegm, therapeutic method to keep the adverse QI flowing downwards eliminating stagnation.
Paradise grass and the Rhizoma Pinelliae two medicine share, and have effect of significant regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.
Rhizoma Alismatis sweet in the mouth, light, cold in nature, enter kidney, urinary bladder channel, there is effect of significant promoting diuresis to eliminate damp pathogen.
Fructus Ligustri Lucidi, the Cortex Eucommiae, Flos puerariae lobatae, Radix Arnebiae (Radix Lithospermi), Herba Cirsii, Semen Persicae, Radix Et Rhizoma Rhei, paradise grass, the Rhizoma Pinelliae and the Rhizoma Alismatis ten taste medicine adjuvant jointly in the side of composition.
In pharmaceutical composition of the present invention, Cacumen Securinegae Suffruticosae, Herba Lysimachiae Clethroids, Pedicellus Melo, Fructus Ligustri Lucidi, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Herba Cirsii, Flos puerariae lobatae, Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, paradise grass, Radix Curcumae, Radix Et Rhizoma Rhei, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Semen Cassiae, Pericarpium Citri Reticulatae, Semen Persicae and choline chloride, Ursodeoxycholic Acid Tablets share, organic assembling, dialectical compatibility and mutually assisting a ruler in governing a country, have that significant heat clearing away dispels that fat protects the liver, dissipating blood stasis eliminating dampness by diuresis spleen invigorating, promoting the circulation of QI and reducing phlegm hemostasia effect, soothing the liver fat of dispelling, can effectively treat cat fatty liver syndrome.In addition, this pharmaceutical composition medical material used, both without any toxicity, also without any drug dependence, can be applicable in the medicine of preparation treatment cat fatty liver syndrome.
Cacumen Securinegae Suffruticosae in pharmaceutical composition described in the present invention, Herba Lysimachiae Clethroids, Pedicellus Melo, Fructus Ligustri Lucidi, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Herba Cirsii, Flos puerariae lobatae, Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, paradise grass, Radix Curcumae, Radix Et Rhizoma Rhei, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Semen Cassiae, Pericarpium Citri Reticulatae, Semen Persicae well known to a person skilled in the art, can by commercial sources buy from a medical store obtain or by method disclosed in prior art cultivation, gathering prepares, its specification meets country or industry standard.
In embodiments more provided by the invention, pharmaceutical composition of the present invention is made up of following raw material: Cacumen Securinegae Suffruticosae 60 parts, Herba Lysimachiae Clethroids 60 parts, Pedicellus Melo 60 parts, Fructus Ligustri Lucidi 50 parts, the Cortex Eucommiae 50 parts, Radix Arnebiae (Radix Lithospermi) 50 parts, Flos puerariae lobatae 50 parts, Rhizoma Polygoni Cuspidati 50 parts, Fructus Atriplicis Sibiricae 40 parts, Herba Cirsii 40 parts, Herba Artemisiae Scopariae 40 parts, paradise grass 40 parts, Radix Curcumae 40 parts, Radix Et Rhizoma Rhei 40 parts, Radix Bupleuri 40 parts, Rhizoma Alismatis 35 parts, the Rhizoma Pinelliae 35 parts, Semen Cassiae 35 parts, Pericarpium Citri Reticulatae 35 parts, 30 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts
In embodiments more provided by the invention, pharmaceutical composition of the present invention is made up of following raw material: Cacumen Securinegae Suffruticosae 40 parts, Herba Lysimachiae Clethroids 40 parts, Pedicellus Melo 40 parts, Fructus Ligustri Lucidi 30 parts, the Cortex Eucommiae 30 parts, Radix Arnebiae (Radix Lithospermi) 30 parts, Flos puerariae lobatae 30 parts, Rhizoma Polygoni Cuspidati 30 parts, Fructus Atriplicis Sibiricae 20 parts, Herba Cirsii 20 parts, Herba Artemisiae Scopariae 20 parts, paradise grass 20 parts, Radix Curcumae 20 parts, Radix Et Rhizoma Rhei 20 parts, Radix Bupleuri 20 parts, Rhizoma Alismatis 15 parts, the Rhizoma Pinelliae 15 parts, Semen Cassiae 15 parts, Pericarpium Citri Reticulatae 15 parts, 10 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
In embodiments more provided by the invention, pharmaceutical composition of the present invention is made up of following raw material: Cacumen Securinegae Suffruticosae 50 parts, Herba Lysimachiae Clethroids 50 parts, Pedicellus Melo 50 parts, Fructus Ligustri Lucidi 40 parts, the Cortex Eucommiae 40 parts, Radix Arnebiae (Radix Lithospermi) 40 parts, Flos puerariae lobatae 40 parts, Rhizoma Polygoni Cuspidati 40 parts, Fructus Atriplicis Sibiricae 30 parts, Herba Cirsii 30 parts, Herba Artemisiae Scopariae 30 parts, paradise grass 30 parts, Radix Curcumae 30 parts, Radix Et Rhizoma Rhei 30 parts, Radix Bupleuri 30 parts, Rhizoma Alismatis 25 parts, the Rhizoma Pinelliae 25 parts, Semen Cassiae 25 parts, Pericarpium Citri Reticulatae 25 parts, 20 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
Present invention also offers the preparation method of described pharmaceutical composition.
A preparation method for pharmaceutical composition, comprises
Step 1: take Herba Lysimachiae Clethroids, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Rhizoma Polygoni Cuspidati, paradise grass, Radix Et Rhizoma Rhei, Semen Cassiae pulverizing by proportioning raw materials, reflux, extract, after ethanol merceration, collecting by filtration filtrate;
Step 2: take Cacumen Securinegae Suffruticosae, Pedicellus Melo, Fructus Ligustri Lucidi, Herba Cirsii, Flos puerariae lobatae, Herba Artemisiae Scopariae, Radix Curcumae, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Semen Persicae pulverizing by proportioning raw materials, collect filtrate after water extraction;
Step 3: step 1 gained filtrate and step 2 gained filtrate are merged, adds choline chloride powder and Ursodeoxycholic Acid Tablets by proportioning.
In preparation method of the present invention, ethanol merceration described in step 1 and reflux, extract, are this area general extraction methods.
As preferably, in preparation method of the present invention, ethanol merceration described in step 1 is the medical material that 90% ethanol submergence is pulverized, dipping 1d.
Preferably, 3cm is exceeded again after the medical material that ethanol submergence is pulverized.In dipping process, preferably often jolting or stirring, to accelerate to leach.
As preferably, in preparation method of the present invention, reflux, extract, described in step 1 is alcohol reflux 1-3 time, each 30min-60min.
In some embodiments, described reflux, extract, is the medical material reflux, extract, 60min of ethanol merceration, filters after cooling, adds the ethanol of 90% in medicinal residues again, 2 reflux, extract, 30min, cooled and filtered.
In preparation method of the present invention, described in step 2, water extraction is taken as this area general extraction methods.
As preferably, in preparation method of the present invention, water extraction described in step 2 is taken as and adds 8 times of water gagings, and 65 DEG C are extracted 1-3 time, each 3-6h.
In some embodiments, in preparation method of the present invention, step 2 is filtered the medical material pulverized before water extraction.Be preferably, 100 mesh screen.
In the preparation method of pharmaceutical composition of the present invention, step gained filtrate and step 2 gained filtrate merge by step 3, add choline chloride powder and Ursodeoxycholic Acid Tablets by proportioning.
Wherein, preferably, crude drug 1.28g/mL-1.42g/mL is contained in described pharmaceutical composition.
Present invention also offers pharmaceutical composition prepared by above-mentioned preparation method.
In a specific embodiment, the present invention evaluates the clinical efficacy of pharmaceutical composition of the present invention respectively from Clinical symptom and sign situation of change, changes of liver function situation, Blood Lipid and general curative effect angle, result shows the main clinic symptoms of pharmaceutical composition group of the present invention and sign change will significantly better than Chinese drug-treated group, Western medicine group and matched group, and difference extremely significantly (P<0.01); And adopt pharmaceutical composition group of the present invention to treat rear ALT, AST with this group before treatment, difference extremely significantly (P<0.01), compare after treating with Chinese drug-treated group, Western medicine group, significant difference (P<0.05).After adopting pharmaceutical composition group of the present invention to treat, TC, TG all have obvious reduction, compare after treating with other 3 groups, and difference is (P<0.01) or significant difference (P<0.05) extremely significantly.And cat fatty liver syndrome therapeutic effect proves, pharmaceutical composition group therapeutic effect of the present invention is best, and cure rate reaches 88.89%, total effective rate 100.00%, and difference extremely significantly (P<0.01) compared with other two groups.Show, pharmaceutical composition of the present invention has clear and definite curative effect to the treatment of cat fatty liver syndrome, has good use value.
Therefore, present invention also offers the application of described pharmaceutical composition in the medicine of preparation treatment cat fatty liver.
Pharmaceutical composition of the present invention can be prepared into various veterinary drug conventional formulation by this area conventional formulation method, such as, can add and can accept adjuvant in the pharmaceutical composition of effective dose of the present invention, such as disintegrating agent, lubricant, adhesive, dispersant etc., with conventional formulation method, be prepared into various common dosage forms.The present invention preferably makes powder, water solube powder, solution, injection or tablet.
To those skilled in the art, when knowing active component, according to the formulation method of routine, can make various pharmaceutical products easily, the adjuvant simultaneously adopted in preparation is also for well known in the art.
Using dosage and the using method of pharmaceutical composition of the present invention depend on factors, comprise the subjective judgment of suffering from cat age, body weight, natural health situation, nutriture, the activity intensity of compound, service time, metabolic rate, the course of disease order of severity and diagnosis and treatment doctor.Those skilled in the art easily can determine using dosage and the using method of described pharmaceutical composition according to above-mentioned factor.
From above technical scheme, pharmaceutical composition of the present invention selects Cacumen Securinegae Suffruticosae, Herba Lysimachiae Clethroids, Pedicellus Melo, Fructus Ligustri Lucidi, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Herba Cirsii, Flos puerariae lobatae, Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, paradise grass, Radix Curcumae, Radix Et Rhizoma Rhei, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Semen Cassiae, Pericarpium Citri Reticulatae, Semen Persicae and choline chloride, ursodesoxycholic acid to make by certain part by weight, formula is simple, organic assembling, dialectical compatibility and mutually assisting a ruler in governing a country, have that significant heat clearing away dispels that fat protects the liver, dissipating blood stasis eliminating dampness by diuresis spleen invigorating, promoting the circulation of QI and reducing phlegm hemostasia effect, soothing the liver fat of dispelling, can effectively treat cat fatty liver syndrome.Through clinical treatment statistical confirmation, cure rate can reach 88.89%, effective percentage 100%.Herba Lysimachiae Clethroids, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Rhizoma Polygoni Cuspidati, paradise grass, Radix Et Rhizoma Rhei, Semen Cassiae are pulverized by the preparation method of pharmaceutical composition of the present invention, reflux, extract, after ethanol merceration, collecting by filtration filtrate, Cacumen Securinegae Suffruticosae, Pedicellus Melo, Fructus Ligustri Lucidi, Herba Cirsii, Flos puerariae lobatae, Herba Artemisiae Scopariae, Radix Curcumae, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Semen Persicae are pulverized, after water extraction, collects filtrate, two filtrates merge, add choline chloride powder and Ursodeoxycholic Acid Tablets to obtain, farthest remain the effective ingredient of each raw material, solve Chinese medicine powder crude fiber content high simultaneously, effective ingredient is difficult to the deficiency of stripping, use convenient, absorb rapidly, the medicine composite for curing cat fatty liver syndrome Be very effective prepared, crude drug source is extensive simultaneously, cost is low, simple to operate, have no side effect, be easy to suffer from cat absorb, be suitable for suitability for industrialized production, for promoting that the sound development of raising pets industry has very important economy and social meaning.
For a better understanding of the present invention, below in conjunction with specific embodiment, the present invention is described in detail.
Embodiment 1: pharmaceutical composition of the present invention
Cacumen Securinegae Suffruticosae 60 parts, Herba Lysimachiae Clethroids 60 parts, Pedicellus Melo 60 parts, Fructus Ligustri Lucidi 50 parts, the Cortex Eucommiae 50 parts, Radix Arnebiae (Radix Lithospermi) 50 parts, Flos puerariae lobatae 50 parts, Rhizoma Polygoni Cuspidati 50 parts, Fructus Atriplicis Sibiricae 40 parts, Herba Cirsii 40 parts, Herba Artemisiae Scopariae 40 parts, paradise grass 40 parts, Radix Curcumae 40 parts, Radix Et Rhizoma Rhei 40 parts, Radix Bupleuri 40 parts, Rhizoma Alismatis 35 parts, the Rhizoma Pinelliae 35 parts, Semen Cassiae 35 parts, Pericarpium Citri Reticulatae 35 parts, 30 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
Embodiment 2: pharmaceutical composition of the present invention
Cacumen Securinegae Suffruticosae 40 parts, Herba Lysimachiae Clethroids 40 parts, Pedicellus Melo 40 parts, Fructus Ligustri Lucidi 30 parts, the Cortex Eucommiae 30 parts, Radix Arnebiae (Radix Lithospermi) 30 parts, Flos puerariae lobatae 30 parts, Rhizoma Polygoni Cuspidati 30 parts, Fructus Atriplicis Sibiricae 20 parts, Herba Cirsii 20 parts, Herba Artemisiae Scopariae 20 parts, paradise grass 20 parts, Radix Curcumae 20 parts, Radix Et Rhizoma Rhei 20 parts, Radix Bupleuri 20 parts, Rhizoma Alismatis 15 parts, the Rhizoma Pinelliae 15 parts, Semen Cassiae 15 parts, Pericarpium Citri Reticulatae 15 parts, 10 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
Embodiment 3: pharmaceutical composition of the present invention
Cacumen Securinegae Suffruticosae 50 parts, Herba Lysimachiae Clethroids 50 parts, Pedicellus Melo 50 parts, Fructus Ligustri Lucidi 40 parts, the Cortex Eucommiae 40 parts, Radix Arnebiae (Radix Lithospermi) 40 parts, Flos puerariae lobatae 40 parts, Rhizoma Polygoni Cuspidati 40 parts, Fructus Atriplicis Sibiricae 30 parts, Herba Cirsii 30 parts, Herba Artemisiae Scopariae 30 parts, paradise grass 30 parts, Radix Curcumae 30 parts, Radix Et Rhizoma Rhei 30 parts, Radix Bupleuri 30 parts, Rhizoma Alismatis 25 parts, the Rhizoma Pinelliae 25 parts, Semen Cassiae 25 parts, Pericarpium Citri Reticulatae 25 parts, 20 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
Embodiment 4: the preparation method of pharmaceutical composition of the present invention
Each component is taken by proportioning raw materials, after Herba Lysimachiae Clethroids wherein, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Rhizoma Polygoni Cuspidati, paradise grass, Radix Et Rhizoma Rhei, Semen Cassiae powder are broken into coarse powder, adopt the mode of cold-maceration, first the medical material of pulverizing is put into the ethanol that macerator adds 90%, exceed 3cm again after submergence, build lid, dipping 1d, in dipping process, should often jolting or stirring, to accelerate to leach.Then reflux, extract, 60min, filters after cooling, adds the ethanol of 90% in medicinal residues again, and do the 2nd backflow, about 0.5h, cooled and filtered, collects the filtrate of 2 times, and autoclaving after concentrated, obtains medicinal liquid 1;
Each component is taken by proportioning raw materials, 100 mesh sieves are crossed after Cacumen Securinegae Suffruticosae wherein, Pedicellus Melo, Fructus Ligustri Lucidi, Herba Cirsii, Flos puerariae lobatae, Herba Artemisiae Scopariae, Radix Curcumae, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Semen Persicae being pulverized, add 8 times of water gagings, 65 DEG C of water-bath 3h are put into after sealing, leach medicinal liquid, repeatedly extract 3 times, merge gained filtrate, autoclaving after concentrated, obtains medicinal liquid 2;
By also 2-in-1 to medicinal liquid 1 and medicinal liquid, take choline chloride powder, Ursodeoxycholic Acid Tablets by proportioning, distinguished pulverize, join medicinal liquid 1 with the amalgamation liquid of medicinal liquid 2, obtain described pharmaceutical composition, containing crude drug 1.28g/mL-1.42g/mL.
Embodiment 5: clinical effect trial
1, method
Select pet clinic of certain scale 10, select trouble cat 72 example that cat fatty liver syndrome occurs, age 2-12 year, wherein female 56 examples, male 16 examples.Trouble cat is divided into 4 groups, be respectively of the present invention group, Chinese drug-treated group, Western medicine group and matched group.Treatment period in a medicine strengthens feeding and management to trouble cat, ensures sufficient drinking-water, feeds to soft digestible food.
Observation item:
(1) symptom variation of treatments period;
(2) liver function: comprise total bilirubin (TBIL), gamma glutamyl transpeptidase (GGT), ALT, AST.
(3) blood fat: comprise T-CHOL (TC), TG.
Above-mentioned lab work is respectively looked into once respectively at pre-treatment and after treatment, and treatments period observes the symptoms at any time, sign change, and itemized record suffer from the untoward reaction that cat may occur.
Curative effect determinate standard:
Cure: trouble cat fatty liver syndrome symptom, sign disappear substantially, and laboratory checking index recovers normal substantially.
Take a turn for the better: suffer from cat fatty liver syndrome symptom major part and disappear, ALT, rate and blood-lipid decreased >30%.
Invalid: not reach above-mentioned standard or add severe one.
Of the present invention group: pharmaceutical composition described in embodiment 1 is made concentrated medicament according to method described in embodiment 4, dosage is 5ml/Kg body weight, divides morning and afternoon every day and gavages for 2 times.Medicine temperature control is at 40-50 DEG C of decoction being taken warmly.
Chinese drug-treated group: for pharmaceutical composition described in embodiment 1 removes Western medicine part (choline chloride powder, Ursodeoxycholic Acid Tablets), according to method described in embodiment 4, do not add Western medicine part (choline chloride powder, Ursodeoxycholic Acid Tablets) and make concentrated medicament.Dosage is 5ml/Kg body weight, divides morning and afternoon every day and gavages for 2 times.Medicine temperature control is at 40-50 DEG C of decoction being taken warmly.
Western medicine group: oral choline chloride powder, 50mg/Kg body weight, divides and gavage for 2 times morning and afternoon every day.Ursodeoxycholic Acid Tablets, dosage is 10mg/Kg body weight, divides morning and afternoon every day and gavages for 2 times.
Matched group: do not adopt above-mentioned any Drug therapy.
In addition, fatty liver syndrome is suffered from cat and mostly be there will be dehydration in various degree, should fluid infusion in time; Vomit heavier, the potassium ion lost will be supplemented in time, can quiet note darrow injection, to correct hypokalemia.As occurred, serious low serum p, hypomagnesemia also will supplement accordingly.Emesis can use metoclopramide injection, and dosage is 0.3mg/kg body weight, intramuscular injection, to promote gastric peristalsis, suppresses vomiting.Long-term anorexia can use vitamin B complex injection 1ml, intramuscular injection, every day 1 time.Promote fat-splitting medicine in hepatocyte, available coenzyme A200IU, adenosine triphosphate (ATP) 15mg, be dissolved in normal saline iv drip; Inosine 100-400mg/ time, intramuscular injection.For Bleeding control should vitimin supplement K in time, 2 times/d, be used in conjunction 3d.
Treatment time is a course for the treatment of, and each course for the treatment of is 30d, every day at upper and lower noon each medication 1 time.Refer to table 1.
Table 1 suffers from poultry grouping and primary treatments
2, result
72 examples suffer from cat by different dosage regimens, and through 30d treatment, three treatment groups are suffered from cat and started initiatively to take food drinking-water gradually, and do not occur vomiting again, Dermal icterus phenomenon obviously goes down, and hepatic region tenderness phenomenon is mostly eliminated, and the mental status is clearly better.Best with of the present invention group of recovery in three groups.Again all trouble cats are carried out to the inspection of liver function and blood fat, result shows: of the present invention group of most trouble cat is fully recovered.
Main clinic symptoms, sign situation of change before and after 2.1 treatments, refer to table 2.
Table 2 treats front and back main clinic symptoms and sign situation of change
Note: of the present invention group to Chinese drug-treated group, Indexes Comparison that Western medicine group is corresponding, a represents significant difference (P<0.05), and A represents that difference is extremely significantly (P<0.01).
As can be seen from Table 2, suffer from cats after treatment for 4 groups, the main clinic symptoms of of the present invention group and sign change will significantly better than Chinese drug-treated group, Western medicine group and matched groups, and difference extremely significantly (P<0.01); And Chinese drug-treated group and Western medicine group compare, difference is not significantly (P > 0.05); 3 treatment groups compare with matched group, equal significant difference (P<0.05).
Changes of liver function situation before and after 2.2 4 groups of treatments, refers to table 3.
Before and after table 3 liang group treatment, changes of liver function situation compares
Note: after of the present invention group for the treatment of with this group before treatment, A represents that difference is extremely significantly (P<0.01); Compare after treating with Chinese drug-treated group, Western medicine group after of the present invention group for the treatment of, a represents significant difference (P<0.05).
At the end of the course for the treatment of, after of the present invention group for the treatment of, ALT, AST are with this group before treatment, and difference extremely significantly (P<0.01); After of the present invention group for the treatment of, ALT, AST compare after treating with Chinese drug-treated group, Western medicine group, significant difference (P<0.05).
Wherein of the present invention group 18 example suffers from cat ALT recovery has 16 examples, 2 examples of decline more than 30% normally.Chinese drug-treated group 18 example is suffered from cat 13 example and is recovered normal, decline more than 30% 3 examples, decline less than 30% 2 examples.Routine cat 12 example of suffering from of Western medicine group 18 recovers normal, 3 examples of decline more than 30%, and decline less than 30% 3 example.Routine cat 1 example of suffering from of matched group 18 recovers normal, 4 examples of decline more than 30%, and decline less than 30% 13 example.
Blood Lipid before and after 2.3 4 groups of treatments, refers to table 4.
A table 4 liang group treatment front and back Blood Lipid situation compares (mmol/L, )
Note: with this group before treatment, a represents significant difference (P<0.05), and A represents that difference is extremely significantly (P<0.01); Compare with after treatment of control group, b represents significant difference (P<0.05), and B represents that difference extremely significantly (P<0.01).
3 treatment groups suffer from cat after treatment, and TC, TG all have obvious reduction, and compare after of the present invention group of TC treatment with after comparing before treatment and treat with other 3 groups, difference extremely significantly (P<0.01).The treatment of TG treatment group is rear and treat self poor heteropole front significantly (P<0.01), after treating with Chinese drug-treated group and Western medicine group, comparing difference significantly (P<0.05), with heteropole poor after treatment of control group remarkable (P<0.01).
Wherein of the present invention group 18 example trouble cat TC recovers there are 15 examples normally, 2 examples of decline more than 30%, 1 example of decline less than 30%.Chinese drug-treated group 18 example is suffered from cat 12 example and is recovered normal, decline more than 30% 3 examples, decline less than 30% 3 examples.Routine cat 11 example of suffering from of Western medicine group 18 recovers normal, 3 examples of decline more than 30%, and decline less than 30% 4 example.Routine cat 1 example of suffering from of matched group 18 recovers normal, 3 examples of decline more than 30%, and decline less than 30% 14 example.
2.4 4 groups of comparitive study.
72 examples suffer from cat by different dosage regimens, and after the treatment of 1 course for the treatment of, the indices before and after comprehensive above-mentioned treatment judges, the therapeutic effect of each group is in table 5.
The various therapeutic scheme therapeutic effect of table 5
Group Treatment quantity Cure Take a turn for the better Invalid Cure rate (%) Total effective rate (%)
Of the present invention group 18 16 2 0 88.89 A 100.00
Chinese drug-treated group 18 13 3 2 72.22 B 88.89
Western medicine group 18 12 3 3 66.67 B 83.33
Matched group 18 1 4 13 5.56 27.78
Note: treat compare with other 2 groups for of the present invention group, A represents that difference is extremely significantly (P<0.01); Compare with matched group, B represents that difference extremely significantly (P<0.01).
From table 5,3 groups of medicines have different therapeutic effect to cat fatty liver syndrome, and wherein best with of the present invention group of therapeutic effect, cure rate reaches 88.89%, total effective rate 100.00%, difference is extremely significantly (P<0.01) compared with other two groups; Chinese drug-treated group is taken second place, Western medicine group again, Chinese drug-treated group and Western medicine group difference not significantly (P>0.05), these two groups with matched group difference extremely significantly (P<0.01), and matched group does not have therapeutical effect.
According to the method described above, respectively pharmaceutical composition described in embodiment 2 and embodiment 3 is made concentrated medicament according to method described in embodiment 4, compare with corresponding Chinese drug-treated group and Western medicine group, observe clinical efficacy, result is similar to the pharmaceutical composition clinical efficacy result described in embodiment 1.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.

Claims (10)

1. a pharmaceutical composition, is characterized in that, is made up of the crude drug of following weight portion:
Cacumen Securinegae Suffruticosae 40-60 part, Herba Lysimachiae Clethroids 40-60 part, Pedicellus Melo 40-60 part, Fructus Ligustri Lucidi 30-50 part, Cortex Eucommiae 30-50 part, Radix Arnebiae (Radix Lithospermi) 30-50 part, Flos puerariae lobatae 30-50 part, Rhizoma Polygoni Cuspidati 30-50 part, Fructus Atriplicis Sibiricae 20-40 part, Herba Cirsii 20-40 part, Herba Artemisiae Scopariae 20-40 part, paradise grass 20-40 part, Radix Curcumae 20-40 part, Radix Et Rhizoma Rhei 20-40 part, Radix Bupleuri 20-40 part, Rhizoma Alismatis 15-35 part, Rhizoma Pinelliae 15-35 part, Semen Cassiae 15-35 part, Pericarpium Citri Reticulatae 15-35 part, Semen Persicae 10-30 part, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
2. pharmaceutical composition according to claim 1, it is characterized in that, described raw material medicines in portions by weight number is: Cacumen Securinegae Suffruticosae 60 parts, Herba Lysimachiae Clethroids 60 parts, Pedicellus Melo 60 parts, Fructus Ligustri Lucidi 50 parts, the Cortex Eucommiae 50 parts, Radix Arnebiae (Radix Lithospermi) 50 parts, Flos puerariae lobatae 50 parts, Rhizoma Polygoni Cuspidati 50 parts, Fructus Atriplicis Sibiricae 40 parts, Herba Cirsii 40 parts, Herba Artemisiae Scopariae 40 parts, paradise grass 40 parts, Radix Curcumae 40 parts, Radix Et Rhizoma Rhei 40 parts, Radix Bupleuri 40 parts, Rhizoma Alismatis 35 parts, the Rhizoma Pinelliae 35 parts, Semen Cassiae 35 parts, Pericarpium Citri Reticulatae 35 parts, 30 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
3. pharmaceutical composition according to claim 1, it is characterized in that, described raw material medicines in portions by weight number is: Cacumen Securinegae Suffruticosae 40 parts, Herba Lysimachiae Clethroids 40 parts, Pedicellus Melo 40 parts, Fructus Ligustri Lucidi 30 parts, the Cortex Eucommiae 30 parts, Radix Arnebiae (Radix Lithospermi) 30 parts, Flos puerariae lobatae 30 parts, Rhizoma Polygoni Cuspidati 30 parts, Fructus Atriplicis Sibiricae 20 parts, Herba Cirsii 20 parts, Herba Artemisiae Scopariae 20 parts, paradise grass 20 parts, Radix Curcumae 20 parts, Radix Et Rhizoma Rhei 20 parts, Radix Bupleuri 20 parts, Rhizoma Alismatis 15 parts, the Rhizoma Pinelliae 15 parts, Semen Cassiae 15 parts, Pericarpium Citri Reticulatae 15 parts, 10 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
4. pharmaceutical composition according to claim 1, it is characterized in that, described raw material medicines in portions by weight number is: Cacumen Securinegae Suffruticosae 50 parts, Herba Lysimachiae Clethroids 50 parts, Pedicellus Melo 50 parts, Fructus Ligustri Lucidi 40 parts, the Cortex Eucommiae 40 parts, Radix Arnebiae (Radix Lithospermi) 40 parts, Flos puerariae lobatae 40 parts, Rhizoma Polygoni Cuspidati 40 parts, Fructus Atriplicis Sibiricae 30 parts, Herba Cirsii 30 parts, Herba Artemisiae Scopariae 30 parts, paradise grass 30 parts, Radix Curcumae 30 parts, Radix Et Rhizoma Rhei 30 parts, Radix Bupleuri 30 parts, Rhizoma Alismatis 25 parts, the Rhizoma Pinelliae 25 parts, Semen Cassiae 25 parts, Pericarpium Citri Reticulatae 25 parts, 20 parts, Semen Persicae, 20 parts, choline chloride powder, Ursodeoxycholic Acid Tablets 4 parts.
5. the preparation method of pharmaceutical composition described in claim 1, is characterized in that, comprises
Step 1: take Herba Lysimachiae Clethroids, the Cortex Eucommiae, Radix Arnebiae (Radix Lithospermi), Fructus Atriplicis Sibiricae, Rhizoma Polygoni Cuspidati, paradise grass, Radix Et Rhizoma Rhei, Semen Cassiae pulverizing by proportioning raw materials, reflux, extract, after ethanol merceration, collecting by filtration filtrate;
Step 2: take Cacumen Securinegae Suffruticosae, Pedicellus Melo, Fructus Ligustri Lucidi, Herba Cirsii, Flos puerariae lobatae, Herba Artemisiae Scopariae, Radix Curcumae, Radix Bupleuri, Rhizoma Alismatis, the Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Semen Persicae pulverizing by proportioning raw materials, collect filtrate after water extraction;
Step 3: step gained filtrate and step 2 gained filtrate are merged, adds choline chloride powder and Ursodeoxycholic Acid Tablets by proportioning.
6. preparation method according to claim 5, is characterized in that, ethanol merceration described in step 1 is the medical material that 90% ethanol submergence is pulverized, dipping 1d; Reflux, extract, described in step 1 is reflux, extract, 1-3 time, each 30min-60min.
7. preparation method according to claim 5, it is characterized in that, water extraction described in step 2 is taken as and adds 8 times of water gagings, and 65 DEG C are extracted 1-3 time, each 3-6h.
8. preparation method according to claim 5, is characterized in that, containing crude drug 1.28g/mL-1.42g/mL in described pharmaceutical composition.
9. the application of pharmaceutical composition described in claim 1-4 any one in the medicine of preparation treatment cat fatty liver.
10. treat a pharmaceutical preparation for cat fatty liver, it is characterized in that, by pharmaceutical composition described in the claim 1-4 any one of effective dose with adjuvant can be accepted form.
CN201511017275.7A 2015-12-29 2015-12-29 Pharmaceutical composition for treating cat fatty liver and preparation method thereof Pending CN105535826A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511017275.7A CN105535826A (en) 2015-12-29 2015-12-29 Pharmaceutical composition for treating cat fatty liver and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511017275.7A CN105535826A (en) 2015-12-29 2015-12-29 Pharmaceutical composition for treating cat fatty liver and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105535826A true CN105535826A (en) 2016-05-04

Family

ID=55815709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511017275.7A Pending CN105535826A (en) 2015-12-29 2015-12-29 Pharmaceutical composition for treating cat fatty liver and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105535826A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113398196A (en) * 2021-07-12 2021-09-17 青岛农业大学 Pharmaceutical composition for treating yellow adiposis of minks

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1478508A (en) * 2002-12-31 2004-03-03 临沂新时代药业有限公司 Chinese medicinal composition for treating fatty liver and its preparation method
CN1977872A (en) * 2005-11-29 2007-06-13 丁庆 Function of PES for preventing and treating hyper lipidemia and fat liver
CN101015668A (en) * 2007-01-16 2007-08-15 李卓伦 Fatty liver treating medicine
CN101391079A (en) * 2008-11-06 2009-03-25 徐朝阳 Traditional Chinese medicine for treating fatty liver
CN101468178A (en) * 2007-12-28 2009-07-01 天津天阜康生物技术发展有限公司 Medicament composition for treating fatty liver and preparation method thereof
CN101700390A (en) * 2009-11-16 2010-05-05 郑海波 Oral traditional Chinese medicine composition for treating fatty liver
CN101732657A (en) * 2008-11-19 2010-06-16 北京卓越同创药物研究院 Medicine composition
CN102233119A (en) * 2010-05-08 2011-11-09 博安兄弟制药（中国）有限公司 Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN102397335A (en) * 2011-11-18 2012-04-04 青岛绿曼生物工程有限公司 Pure Chinese medicinal composition for treating poultry fatty liver haemorrhage syndrome and preparation method thereof
CN102657822A (en) * 2012-05-29 2012-09-12 牡丹江医学院 Traditional Chinese medicine for treating fatty liver
CN103071108A (en) * 2012-12-14 2013-05-01 葛晓云 Oral medicine for treating fatty liver
CN103341133A (en) * 2013-07-21 2013-10-09 华菊 Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN103784874A (en) * 2013-12-20 2014-05-14 霍山县中医院 Traditional Chinese medicinal composition for treating obesity fatty liver
CN103933411A (en) * 2014-03-13 2014-07-23 魏玮 Traditional Chinese medicinal composition for treating fatty liver, and preparation method and use thereof
CN104013926A (en) * 2014-06-30 2014-09-03 崔新明 Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver
CN104042802A (en) * 2014-07-10 2014-09-17 崔新明 Traditional Chinese medicine composition capable of treating fatty liver
CN104127602A (en) * 2014-07-29 2014-11-05 秦福玉 Traditional Chinese medicine for treating fatty liver
CN104491751A (en) * 2015-01-09 2015-04-08 王深涧 Traditional Chinese medicine composition for treating fatty liver combined with hyperlipidemia and preparation method of traditional Chinese medicine composition
CN104873566A (en) * 2015-05-29 2015-09-02 中国药科大学 Pharmaceutical composition with antihepatitis activity and application of pharmaceutical composition
CN105079676A (en) * 2015-09-18 2015-11-25 宋克垣 Medicine for treating fatty liver and preparing method of medicine
CN105106826A (en) * 2015-08-19 2015-12-02 廉宇航 Chinese herba preparation for treating nonalcoholic steatohepatitis of florida softshell turtles and preparation method of Chinese herba preparation
CN105250411A (en) * 2015-11-11 2016-01-20 吉林农业大学 Medicine composition for treating cat fatty liver syndrome and preparation method thereof

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1478508A (en) * 2002-12-31 2004-03-03 临沂新时代药业有限公司 Chinese medicinal composition for treating fatty liver and its preparation method
CN1977872A (en) * 2005-11-29 2007-06-13 丁庆 Function of PES for preventing and treating hyper lipidemia and fat liver
CN101015668A (en) * 2007-01-16 2007-08-15 李卓伦 Fatty liver treating medicine
CN101468178A (en) * 2007-12-28 2009-07-01 天津天阜康生物技术发展有限公司 Medicament composition for treating fatty liver and preparation method thereof
CN101391079A (en) * 2008-11-06 2009-03-25 徐朝阳 Traditional Chinese medicine for treating fatty liver
CN101732657A (en) * 2008-11-19 2010-06-16 北京卓越同创药物研究院 Medicine composition
CN101700390A (en) * 2009-11-16 2010-05-05 郑海波 Oral traditional Chinese medicine composition for treating fatty liver
CN102233119A (en) * 2010-05-08 2011-11-09 博安兄弟制药（中国）有限公司 Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN102397335A (en) * 2011-11-18 2012-04-04 青岛绿曼生物工程有限公司 Pure Chinese medicinal composition for treating poultry fatty liver haemorrhage syndrome and preparation method thereof
CN102657822A (en) * 2012-05-29 2012-09-12 牡丹江医学院 Traditional Chinese medicine for treating fatty liver
CN103071108A (en) * 2012-12-14 2013-05-01 葛晓云 Oral medicine for treating fatty liver
CN103341133A (en) * 2013-07-21 2013-10-09 华菊 Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN103784874A (en) * 2013-12-20 2014-05-14 霍山县中医院 Traditional Chinese medicinal composition for treating obesity fatty liver
CN103933411A (en) * 2014-03-13 2014-07-23 魏玮 Traditional Chinese medicinal composition for treating fatty liver, and preparation method and use thereof
CN104013926A (en) * 2014-06-30 2014-09-03 崔新明 Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver
CN104042802A (en) * 2014-07-10 2014-09-17 崔新明 Traditional Chinese medicine composition capable of treating fatty liver
CN104127602A (en) * 2014-07-29 2014-11-05 秦福玉 Traditional Chinese medicine for treating fatty liver
CN104491751A (en) * 2015-01-09 2015-04-08 王深涧 Traditional Chinese medicine composition for treating fatty liver combined with hyperlipidemia and preparation method of traditional Chinese medicine composition
CN104873566A (en) * 2015-05-29 2015-09-02 中国药科大学 Pharmaceutical composition with antihepatitis activity and application of pharmaceutical composition
CN105106826A (en) * 2015-08-19 2015-12-02 廉宇航 Chinese herba preparation for treating nonalcoholic steatohepatitis of florida softshell turtles and preparation method of Chinese herba preparation
CN105079676A (en) * 2015-09-18 2015-11-25 宋克垣 Medicine for treating fatty liver and preparing method of medicine
CN105250411A (en) * 2015-11-11 2016-01-20 吉林农业大学 Medicine composition for treating cat fatty liver syndrome and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王广龙等: "猫脂肪肝的诊断和分组治疗临床效果观察", 《黑龙江畜牧兽医》 *
王明华等: "中西药结合治疗猫脂肪肝一例", 《吉林畜牧兽医》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113398196A (en) * 2021-07-12 2021-09-17 青岛农业大学 Pharmaceutical composition for treating yellow adiposis of minks

Similar Documents

Publication Publication Date Title
CN103830577B (en) A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease
CN104324189A (en) Intestine-moistening and bowel-releasing health-caring product
CN104524071A (en) Pharmaceutical composition for treating primary renal disease and application thereof
CN103705796A (en) Medicinal composition for treating diarrhea, and preparation method thereof
CN103405743B (en) Drug preparation for infantile diarrhea
CN105535826A (en) Pharmaceutical composition for treating cat fatty liver and preparation method thereof
CN104524292A (en) Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity
CN100389796C (en) Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method
CN103705835B (en) Medicine being used for the treatment of cad pig and preparation method thereof
CN103417799A (en) Applications of a traditional Chinese medicine composition in preparing medicines treating anaemia
CN106109908A (en) A kind of mongolian medicine compositions treating sheep babesiasis
CN105616581A (en) Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof
CN102008624B (en) Taiji inoculating prescription for treating sterility and preparation method thereof
CN103751692B (en) Special invigorating capsule of a kind of Testis et penis callorhini and preparation method thereof
CN103689298B (en) Feed being used for the treatment of cad pig and preparation method thereof
CN1245199C (en) Oral medicinal composition for treating diabetes
CN104436049A (en) Traditional Chinese medicine composition for treating heart disease
CN104547738A (en) Traditional Chinese medicine preparation for treating obesity and preparation method of traditional Chinese medicine preparation
CN100394930C (en) Application of cassia seed in preparation of lead-remove promoting drug or health-caring product
CN105250411B (en) A kind of pharmaceutical composition and preparation method thereof for treating cat fatty liver syndrome
CN109663131A (en) The composition of relax bowel and defecation
CN103611035A (en) Traditional Chinese medicine composition for treating phlegm-dampness stagnation type fatty liver
CN113908208B (en) Liver-protecting pharmaceutical composition and preparation method and application thereof
CN106266334A (en) A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application
CN1857686A (en) Medicine composition for treating fatty liver and its preparing method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160504

RJ01 Rejection of invention patent application after publication